Secreted Mucosal Antimicrobials in the Female Reproductive Tract that are Important to Consider for HIV Prevention

American Journal of Reproductive Immunology

Volumn 71, Issue 6, 2014, Pages 575-588

  Ghosh, Mimi ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Antimicrobials; Cervical vaginal lavage; Female reproductive tract; HIV; Hormones; Sexually transmitted infections

Indexed keywords

ALPHA DEFENSIN; ANTITHROMBIN III; BETA DEFENSIN 1; BETA DEFENSIN 2; BETA DEFENSIN 3; BETA DEFENSIN 4; CALGRANULIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYSTATIN B; ELAFIN; LACTOFERRIN; LYSOZYME; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; POLYPEPTIDE ANTIBIOTIC AGENT; SERINE PROTEINASE INHIBITOR; SERPIN A1; SERPIN A3; SERPIN B; STEFIN A; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; THROMBOSPONDIN; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ARTICLE; FEMALE GENITAL SYSTEM; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; SEXUALLY TRANSMITTED DISEASE; UTERINE ENDOCERVIX; UTERINE TUBE; VAGINA; FEMALE; HIV INFECTIONS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MUCOSA; MUCOSAL IMMUNITY; SECRETION (PROCESS); SPERM; VAGINAL LAVAGE;

ANTI-HIV AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION; MUCOUS MEMBRANE; SEMEN; VAGINAL DOUCHING;

EID: 84900805500     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12250     Document Type: Article

References (181)

1. Anonymous 2013. UNAIDS Global Factsheet.
2. Henry J Kaiser Family Foundation. 2012. http://kff.org/global-health-policy/fact-sheet/the-global-hivaids-epidemic/.
3. Iqbal SM, Kaul R: Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008; 59:44-54. doi:10.1111/j.1600-0897.2007.00563.x.
4. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TCRakai Project Team: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153. doi:10.1016/S0140-6736(00)04331-2.
5. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team: Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3:77ra29. doi: 10.1126/scitranslmed.3001888.
6. Hickey DK, Patel MV, Fahey JV, Wira CR: Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011; 88:185-194. doi:10.1016/j.jri.2011.01.005.
7. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852. doi:10.1371/journal.ppat.1000852.
8. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, Rossoll RM, Wira CR: Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol 2008; 1:317-325. doi:10.1038/mi.2008.20.
9. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, Ochiel DO: Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2010; 63:544-565. doi:10.1111/j.1600-0897.2010.00842.x.
10. Carias AM, McCoombe S, McRaven M, Anderson M, Galloway N, Vandergrift N, Fought AJ, Lurain J, Duplantis M, Veazey RS, Hope TJ: Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol 2013; 87:11388-11400. doi:10.1128/JVI.01377-13.
11. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ: Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4680-4687. doi:10.1073/pnas.1002611107.
12. Sabatte J, Remes Lenicov F, Cabrini M, Rodriguez Rodrigues C, Ostrowski M, Ceballos A, Amigorena S, Geffner J: The role of semen in sexual transmission of HIV: beyond a carrier for virus particles. Microbes Infect 2011; 13:977-982. doi:10.1016/j.micinf.2011.06.005.
13. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:1059-1071. doi:10.1016/j.cell.2007.10.014.
14. Roan NR, Munch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC: The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol 2009; 83:73-80. doi:10.1128/JVI.01366-08.
15. Balandya E, Sheth S, Sanders K, Wieland-Alter W, Lahey T: Semen protects CD4 + target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J Immunol 2010; 185:7596-7604. doi:10.4049/jimmunol.1002846.
16. Fanibunda SE, Velhal SM, Raghavan VP, Bandivdekar AH: CD4 independent binding of HIV gp120 to mannose receptor on human spermatozoa. J Acquir Immune Defic Syndr 2008; 48:389-397. doi:10.1097/QAI.0b013e318179a0fb.
17. Cardona-Maya W, Velilla PA, Montoya CJ, Cadavid A, Rugeles MT: In vitro human immunodeficiency virus and sperm cell interaction mediated by the mannose receptor. J Reprod Immunol 2011; 92:1-7. doi:10.1016/j.jri.2011.09.002.
18. Ceballos A, Remes Lenicov F, Sabatte J, Rodriguez Rodrigues C, Cabrini M, Jancic C, Raiden S, Donaldson M, Agustin Pasqualini Jr R, Marin-Briggiler C, Vazquez-Levin M, Capani F, Amigorena S, Geffner J: Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J Exp Med 2009; 206:2717-2733. doi:10.1084/jem.20091579.
19. Saidi H, Jenabian MA, Belec L: Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. AIDS Res Hum Retroviruses 2012; 28:1485-1497. doi:10.1089/AID.2012.0049.
20. Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S: Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol Rev 2013; 37:762-792. doi:10.1111/1574-6976.12029.
21. Mirmonsef P, Gilbert D, Zariffard MR, Hamaker BR, Kaur A, Landay AL, Spear GT: The effects of commensal bacteria on innate immune responses in the female genital tract. Am J Reprod Immunol 2011; 65:190-195. doi:10.1111/j.1600-0897.2010.00943.x.
22. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206:306-335. doi:10.1111/j.0105-2896.2005.00287.x.
23. Ghosh M, Shen Z, Fahey JV, Crist SG, Patel M, Smith JM, Wira CR: Pathogen recognition in the human female reproductive tract: expression of intracellular cytosolic sensors NOD1, NOD2, RIG-1, and MDA5 and response to HIV-1 and Neisseria gonorrhea. Am J Reprod Immunol 2013; 69:41-51. doi:10.1111/aji.12019.
24. Schaefer TM, Fahey JV, Wright JA, Wira CR: Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J Immunol 2005; 174:992-1002.
25. Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC: Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS ONE 2011; 6:e23136. doi:10.1371/journal.pone.0023136.
26. Birse KM, Burgener A, Westmacott GR, McCorrister S, Novak RM, Ball TB: Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection. PLoS ONE 2013; 8:e79505. doi:10.1371/journal.pone.0079505.
27. Dasari S, Pereira L, Reddy AP, Michaels JE, Lu X, Jacob T, Thomas A, Rodland M, Roberts CT Jr, Gravett MG, Nagalla SR: Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res 2007; 6:1258-1268. doi:10.1021/pr0605419.
28. Shaw JL, Smith CR, Diamandis EP: Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007; 6:2859-2865. doi:10.1021/pr0701658.
29. Tang LJ, De Seta F, Odreman F, Venge P, Piva C, Guaschino S, Garcia RC: Proteomic analysis of human cervical-vaginal fluids. J Proteome Res 2007; 6:2874-2883. doi:10.1021/pr0700899.
30. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:7560-7567.
31. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, Mayer K, Wright PF, Kappes JC, Ochsenbauer C, Wira CR: Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE 2010; 5:e11366. doi:10.1371/journal.pone.0011366.
32. Lahey T, Ghosh M, Fahey JV, Shen Z, Mukura LR, Song Y, Cu-Uvin S, Mayer KH, Wright PF, Kappes JC, Ochsenbauer C, Wira CR: Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract. PLoS ONE 2012; 7:e38100. doi:10.1371/journal.pone.0038100.
33. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS ONE 2011; 6:e16475. doi:10.1371/journal.pone.0016475.
34. Valore EV, Park CH, Igreti SL, Ganz T: Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187:561-568.
35. Cole AM, Cole AL: Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27-34. doi:10.1111/j.1600-0897.2007.00561.x.
36. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3:710-720. doi:10.1038/nri1180.
37. Klotman ME, Chang TL: Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6:447-456. doi:10.1038/nri1860.
38. Verani A, Lusso P: Chemokines as natural HIV antagonists. Curr Mol Med 2002; 2:691-702.
39. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ: Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003; 74:448-455.
40. Oppenheim JJ, Biragyn A, Kwak LW, Yang D: Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62(Suppl 2):ii17-ii21.
41. Drannik AG, Henrick BM, Rosenthal KL: War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 2011; 39:1427-1432. doi:10.1042/BST0391427.
42. Scott A, Weldon S, Taggart CC: SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 2011; 39:1437-1440. doi:10.1042/BST0391437.
43. Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR: Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2010; 129:207-219. doi:10.1111/j.1365-2567.2009.03165.x.
44. Fahey JV, Wira CR: Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J Infect Dis 2002; 185:1606-1613. doi:10.1086/340512.
45. Aboud L, Ball TB, Tjernlund A, Burgener A: The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV. Am J Reprod Immunol 2014; 71:12-23. doi:10.1111/aji.12166.
46. Madsen J, Gaiha GD, Palaniyar N, Dong T, Mitchell DA, Clark HW: Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells. PLoS ONE 2013; 8:e59047. doi:10.1371/journal.pone.0059047.
47. Gaiha GD, Dong T, Palaniyar N, Mitchell DA, Reid KB, Clark HW: Surfactant protein A binds to HIV and inhibits direct infection of CD4 + cells, but enhances dendritic cell-mediated viral transfer. J Immunol 2008; 181:601-609.
48. Hartshorn KL: Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed) 2010; 2:527-546.
49. Crombie R: Mechanism of thrombospondin-1 anti-HIV-1 activity. AIDS Patient Care STDS 2000; 14:211-214. doi:10.1089/108729100317821.
50. Leth-Larsen R, Floridon C, Nielsen O, Holmskov U: Surfactant protein D in the female genital tract. Mol Hum Reprod 2004; 10:149-154. doi:10.1093/molehr/gah022.
51. MacNeill C, Umstead TM, Phelps DS, Lin Z, Floros J, Shearer DA, Weisz J: Surfactant protein A, an innate immune factor, is expressed in the vaginal mucosa and is present in vaginal lavage fluid. Immunology 2004; 111:91-99.
52. Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ: Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS ONE 2013; 8:e76176. doi:10.1371/journal.pone.0076176.
53. Gipson IK: Mucins of the human endocervix. Front Biosci (Schol Ed) 2001; 6:D1245-D1255.
54. Gipson IK, Ho SB, Spurr-Michaud SJ, Tisdale AS, Zhan Q, Torlakovic E, Pudney J, Anderson DJ, Toribara NW, Hill JA 3rd: Mucin genes expressed by human female reproductive tract epithelia. Biol Reprod 1997; 56:999-1011.
55. Andersch-Bjorkman Y, Thomsson KA, Holmen Larsson JM, Ekerhovd E, Hansson GC: Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol Cell Proteomics 2007; 6:708-716. doi:10.1074/mcp.M600439-MCP200.
56. Shukair SA, Allen SA, Cianci GC, Stieh DJ, Anderson MR, Baig SM, Gioia CJ, Spongberg EJ, Kauffman SM, McRaven MD, Lakougna HY, Hammond C, Kiser PF, Hope TJ: Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol 2013; 6:427-434. doi:10.1038/mi.2012.87.
57. Radtke AL, Quayle AJ, Herbst-Kralovetz MM: Microbial products alter the expression of membrane-associated mucin and antimicrobial peptides in a three-dimensional human endocervical epithelial cell model. Biol Reprod 2012; 87:132. doi:10.1095/biolreprod.112.103366.
58. Fahey JV, Bodwell JE, Hickey DK, Ghosh M, Muia MN, Wira CR: New approaches to making the microenvironment of the female reproductive tract hostile to HIV. Am J Reprod Immunol 2011; 65:334-343. doi:10.1111/j.1600-0897.2010.00949.x.
59. Singh PK, Tack BF, McCray PB Jr, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000; 279:L799-L805.
60. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-1160. doi:10.1056/NEJMoa021481.
61. Lehrer RI, Ganz T, Szklarek D, Selsted ME: Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J Clin Invest 1988; 81:1829-1835. doi:10.1172/JCI113527.
62. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI: Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998; 42:2206-2214.
63. Daher KA, Selsted ME, Lehrer RI: Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60:1068-1074.
64. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME: Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005; 115:765-773. doi:10.1172/JCI21948.
65. Hristova K, Selsted ME, White SH: Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins. J Biol Chem 1997; 272:24224-24233.
66. Lehrer RI, Lichtenstein AK, Ganz T: Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 1993; 11:105-128. doi:10.1146/annurev.iy.11.040193.000541.
67. Turpin JA, Schaeffer CA, Bu M, Graham L, Buckheit RW Jr, Clanton D, Rice WG: Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor. Antiviral Res 1996; 29:269-277.
68. Konopka K, Shine N, Pretzer E, Duzgunes N: Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity. J Dent Res 1999; 78:1773-1776.
69. Shine NR, Wang SC, Konopka K, Burks EA, Duzgunes N, Whitman CP: Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg Chem 2002; 30:249-263.
70. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV: Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65:196-211. doi:10.1111/j.1600-0897.2011.00970.x.
71. Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW: Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci 2009; 7:17. doi:10.1186/1477-5956-7-17.
72. Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC: Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 2004; 15:1262-1272. doi:10.1091/mbc.E03-06-0360.
73. Horne AW, Stock SJ, King AE: Innate immunity and disorders of the female reproductive tract. Reproduction 2008; 135:739-749. doi:10.1530/REP-07-0564.
74. Wira CR, Fahey JV: A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909-1917. doi:10.1097/QAD.0b013e3283060ea4.
75. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, Otten RA, Heneine W, Hendry RM, McNicholl JM, Kersh EN: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57:261-264. doi:10.1097/QAI.0b013e318220ebd3.
76. Saba E, Origoni M, Taccagni G, Ferrari D, Doglioni C, Nava A, Lisco A, Grivel JC, Margolis L, Poli G: Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunol 2013; 6:1081-1090. doi:10.1038/mi.2013.2.
77. Hwang LY, Scott ME, Ma Y, Moscicki AB: Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol 2011; 88:66-71. doi:10.1016/j.jri.2010.07.008.
78. Madan RP, Carpenter C, Fiedler T, Kalyoussef S, McAndrew TC, Viswanathan S, Kim M, Keller MJ, Fredricks DN, Herold BC: Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS ONE 2012; 7:e40415. doi:10.1371/journal.pone.0040415.
79. Macneill C, de Guzman G, Sousa GE, Umstead TM, Phelps DS, Floros J, Ahn K, Weisz J: Cyclic changes in the level of the innate immune molecule, surfactant protein-a, and cytokines in vaginal fluid. Am J Reprod Immunol 2012; 68:244-250. doi:10.1111/j.1600-0897.2012.01155.x.
80. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007; 21:467-476.
81. King AE, Critchley HO, Kelly RW: Innate immune defences in the human endometrium. Reprod Biol Endocrinol 2003; 1:116.
82. King AE, Critchley HO, Kelly RW: Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol Hum Reprod 2000; 6:191-196.
83. Ghartey JP, Carpenter C, Gialanella P, Rising C, McAndrew TC, Mhatre M, Tugetman J, Einstein MH, Chazotte C, Herold BC: Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol 2012; 207:297.e1-297.e8. doi: 10.1016/j.ajog.2012.07.025.
84. Anderson BL, Ghosh M, Raker C, Fahey J, Song Y, Rouse DJ, Wira CR, Cu-Uvin S: In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women. Am J Obstet Gynecol 2012; 207:65.e1-65.e65.10. doi: 10.1016/j.ajog.2012.04.029.
85. Rollenhagen C, Asin SN: Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol 2011; 4:671-681. doi:10.1038/mi.2011.34.
86. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team: Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26. doi:10.1016/S1473-3099(11)70247-X.
87. Polis CB, Curtis KM: Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797-808. doi:10.1016/S1473-3099(13)70155-5.
88. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, Thongpaeng P, Gorowara M, Thammajaruk N, Chaithongwongwatthana S, Lange JM, Ananworanich J: Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr 2013; 62:534-539. doi:10.1097/QAI.0b013e31827e8f98.
89. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S: Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol 2012; 2012:137192. doi:10.1155/2012/137192.
90. Fleming DC, King AE, Williams AR, Critchley HO, Kelly RW: Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 2003; 79:856-863.
91. Li A, Felix JC, Yang W, Jain JK: Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril 2008; 90:872-875. doi:10.1016/j.fertnstert.2007.01.046.
92. Wira CR, Ghosh M, Smith JM, Shen L, Connor RI, Sundstrom P, Frechette GM, Hill ET, Fahey JV: Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol 2011; 4:335-342. doi:10.1038/mi.2010.72.
93. Ghosh M, Fahey JV, Wira CR: Differential susceptibility of HIV strains to innate immune factors in human cervical-vaginal secretions. Virus Adapt Treat 2010; 2:63-71.
94. Spear GT, al-Harthi L, Sha B, Saarloos MN, Hayden M, Massad LS, Benson C, Roebuck KA, Glick NR, Landay A: A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women. AIDS 1997; 11:1319-1326.
95. Spear GT, Zariffard MR, Chen HY, Anzinger JJ, Anastos K, Rusine J, Gatabazi J, French AL, Cohen M, Landay AL: Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses 2008; 24:973-976. doi:10.1089/aid.2008.0004.
96. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, Fauci AS: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172:151-158.
97. Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS: Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A 1990; 87:782-785.
98. Poli G, Kinter AL, Fauci AS: Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A 1994; 91:108-112.
99. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS: Induction of HIV-1 replication in latently infected CD4 + T cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
100. Hashemi FB, Mollenhauer J, Madsen LD, Sha BE, Nacken W, Moyer MB, Sorg C, Spear GT: Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS 2001; 15:441-449.
101. Stoddard E, Ni H, Cannon G, Zhou C, Kallenbach N, Malamud D, Weissman D: Gp340 promotes transcytosis of human immunodeficiency virus Type 1 in genital tract-derived cell lines and primary endocervical tissue. J Virol 2009; 83:8596-8603. doi:10.1128/JVI.00744-09.
102. El Messaoudi K, Thiry LF, Liesnard C, Van Tieghem N, Bollen A, Moguilevsky N: A human milk factor susceptible to cathepsin D inhibitors enhances human immunodeficiency virus type 1 infectivity and allows virus entry into a mammary epithelial cell line. J Virol 2000; 74:1004-1007.
103. El Messaoudi K, Thiry L, Van Tieghem N, Liesnard C, Englert Y, Moguilevsky N, Bollen A: HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions. AIDS 1999; 13:333-339.
104. Ghosh M, Shen Z, Schaefer TM, Fahey JV, Gupta P, Wira CR: CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Reprod Immunol 2009; 62:60-71. doi:10.1111/j.1600-0897.2009.00713.x.
105. Bretschneider N, Kangaspeska S, Seifert M, Reid G, Gannon F, Denger S: E2-mediated cathepsin D (CTSD) activation involves looping of distal enhancer elements. Mol Oncol 2008; 2:182-190. doi:10.1016/j.molonc.2008.05.004.
106. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K, Hirbod T; Kibera HIV Study Group: Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 2009; 23:309-317. doi:10.1097/QAD.0b013e328321809c.
107. Kaul R, Rebbapragada A, Hirbod T, Wachihi C, Ball TB, Plummer FA, Kimani J, Jaoko W: Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS 2008; 22:2049-2051. doi:10.1097/QAD.0b013e328311ac65.
108. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, Lu W, Porter E, Chang TL: Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 2008; 180:6176-6185.
109. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, Herold BC: Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177:8658-8666.
110. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008; 82:9337-9344. doi:10.1128/JVI.00603-08.
111. Jenssen H, Sandvik K, Andersen JH, Hancock RE, Gutteberg TJ: Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antiviral Res 2008; 79:192-198. doi:10.1016/j.antiviral.2008.03.004.
112. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT: Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103:1516-1521. doi:10.1073/pnas.0508033103.
113. Duffy CL, Phillips SL, Klingelhutz AJ: Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. Virology 2003; 314:196-205.
114. Simhan HN, Anderson BL, Krohn MA, Heine RP, Martinez de Tejada B, Landers DV, Hillier SL: Host immune consequences of asymptomatic Trichomonas vaginalis infection in pregnancy. Am J Obstet Gynecol 2007; 196:59.e1-59.e5. doi: 10.1016/j.ajog.2006.08.035.
115. Yasin B, Harwig SS, Lehrer RI, Wagar EA: Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect Immun 1996; 64:709-713.
116. Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, Zani ML: Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90:284-295. doi:10.1016/j.biochi.2007.09.007.
117. Cederlund A, Agerberth B, Bergman P: Specificity in killing pathogens is mediated by distinct repertoires of human neutrophil peptides. J Innate Immun 2010; 2:508-521. doi:10.1159/000317665.
118. Ghosh M, Rodriguez-Garcia M, Wira CR: Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation. Am J Reprod Immunol 2013; 69(Suppl 1):51-60. doi:10.1111/aji.12027.
119. Mukura LR, Ghosh M, Fahey JV, Cu-Uvin S, Wira CR: Genital tract viral load in HIV Type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity. AIDS Res Hum Retroviruses 2012; 28:1533-1539. doi:10.1089/AID.2011.0394.
120. Jaspan HB, Liebenberg L, Hanekom W, Burgers W, Coetzee D, Williamson AL, Little F, Myer L, Coombs RW, Sodora D, Passmore JA: Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis 2011; 204:1550-1556. doi:10.1093/infdis/jir591.
121. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM: Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497. doi:10.1097/QAD.0b013e32833e5043.
122. Homans J, Christensen S, Stiller T, Wang CH, Mack W, Anastos K, Minkoff H, Young M, Greenblatt R, Cohen M, Strickler H, Karim R, Spencer LY, Operskalski E, Frederick T, Kovacs A: Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr 2012; 60:99-110. doi:10.1097/QAI.0b013e31824aeaaa.
123. Blish CA, McClelland RS, Richardson BA, Jaoko W, Mandaliya K, Baeten JM, Overbaugh J: Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. J Acquir Immune Defic Syndr 2012; 61:436-440. doi:10.1097/QAI.0b013e31826c2edd.
124. Herold BC, Keller MJ, Shi Q, Hoover DR, Carpenter CA, Huber A, Parikh UM, Agnew KJ, Minkoff H, Colie C, Nowicki MJ, D'Souza G, Watts DH, Anastos K: Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr 2013; 63:485-493. doi:10.1097/QAI.0b013e3182961cfc.
125. Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB Jr, O'Neill S, McElvaney NG: Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003; 171:931-937.
126. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, McElvaney NG: Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001; 276:33345-33352. doi:10.1074/jbc.M103220200.
127. Hasan L, Mazzucchelli L, Liebi M, Lis M, Hunger RE, Tester A, Overall CM, Wolf M: Function of liver activation-regulated chemokine/CC chemokine ligand 20 is differently affected by cathepsin B and cathepsin D processing. J Immunol 2006; 176:6512-6522.
128. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J: Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432:73-76.
129. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van Damme J, De Clercq E: CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 1998; 39:175-187.
130. Shaw JL, Diamandis EP: Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. Biol Chem 2008; 389:1409-1419.
131. Shaw JL, Petraki C, Watson C, Bocking A, Diamandis EP: Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol Chem 2008; 389:1513-1522. doi:10.1515/BC.2008.171.
132. Rahman S, Rabbani R, Wachihi C, Kimani J, Plummer FA, Ball TB, Burgener A: Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders. Am J Reprod Immunol 2013; 69:64-72. doi:10.1111/aji.12014.
133. Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdahin S, Mesa C, Brunet S, Wachihi C, Kimani J, Fowke K, Carr S, Plummer F, Ball TB: Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Proteome Res 2011; 10:5139-5149. doi:10.1021/pr200596r.
134. Herold BC, Mesquita PM, Madan RP, Keller MJ: Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65:325-333. doi:10.1111/j.1600-0897.2010.00932.x.
135. Ohlsson K, Bjartell A, Lilja H: Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 1995; 16:64-74.
136. Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW: Antiviral activity of genital tract secretions following oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr 2014. doi:10.1097/QAI.0000000000000110. [Epub ahead of print].
137. Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC: Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 2010; 63:110-119. doi:10.1111/j.1600-0897.2009.00768.x.
138. Hein M, Valore EV, Helmig RB, Uldbjerg N, Ganz T: Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol 2002; 187:137-144.
139. Furci L, Tolazzi M, Sironi F, Vassena L, Lusso P: Inhibition of HIV-1 infection by human alpha-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. PLoS ONE 2012; 7:e45208. doi:10.1371/journal.pone.0045208.
140. Svinarich DM, Gomez R, Romero R: Detection of human defensins in the placenta. Am J Reprod Immunol 1997; 38:252-255.
141. Svinarich DM, Wolf NA, Gomez R, Gonik B, Romero R: Detection of human defensin 5 in reproductive tissues. Am J Obstet Gynecol 1997; 176:470-475.
142. Ma JM, Yang HX: Role of Toll-like receptor 4 and human defensin 5 in primary endocervical epithelial cells. Chin Med J (Engl) 2010; 123:1762-1767.
143. Lehrer RI, Lu W: alpha-Defensins in human innate immunity. Immunol Rev 2012; 245:84-112. doi:10.1111/j.1600-065X.2011.01082.x.
144. Gounder AP, Wiens ME, Wilson SS, Lu W, Smith JG: Critical determinants of human alpha-defensin 5 activity against non-enveloped viruses. J Biol Chem 2012; 287:24554-24562. doi:10.1074/jbc.M112.354068.
145. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC: Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 1998; 152:1247-1258.
146. Cremel M, Berlier W, Hamzeh H, Cognasse F, Lawrence P, Genin C, Bernengo JC, Lambert C, Dieu-Nosjean MC, Delezay O: Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 2005; 78:158-166. doi:10.1189/jlb.0305147.
147. Berlier W, Cremel M, Hamzeh H, Levy R, Lucht F, Bourlet T, Pozzetto B, Delezay O: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:1135-1142. doi:10.1093/humrep/dei496.
148. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:1669-1677. doi:10.1097/QAD.0b013e32832ea643.
149. Patel MV, Fahey JV, Rossoll RM, Wira CR: Innate immunity in the vagina (part I): estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells. Am J Reprod Immunol 2013; 69:463-474. doi:10.1111/aji.12078.
150. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Arien KK: Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS ONE 2012; 7:e43951. doi:10.1371/journal.pone.0043951.
151. Drannik AG, Nag K, Sallenave JM, Rosenthal KL: Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. J Virol 2013; 87:7526-7538. doi:10.1128/JVI.02243-12.
152. King AE, Wheelhouse N, Cameron S, McDonald SE, Lee KF, Entrican G, Critchley HO, Horne AW: Expression of secretory leukocyte protease inhibitor and elafin in human fallopian tube and in an in-vitro model of Chlamydia trachomatis infection. Hum Reprod 2009; 24:679-686. doi:10.1093/humrep/den452.
153. Moriyama A, Shimoya K, Ogata I, Kimura T, Nakamura T, Wada H, Ohashi K, Azuma C, Saji F, Murata Y: Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 1999; 5:656-661.
154. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, Landay A: Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102-1107.
155. Shimoya K, Zhang Q, Temma K, Kimura T, Tsujie T, Tsutsui T, Wasada K, Kanzaki T, Koyama M, Murata Y: Secretory leukocyte protease inhibitor levels in cervicovaginal secretion of elderly women. Maturitas 2006; 54:141-148. doi:10.1016/j.maturitas.2004.02.019.
156. Orfanelli T, Jayaram A, Doulaveris G, Forney LJ, Ledger WJ, Witkin SS: Human Epididymis Protein 4 and Secretory Leukocyte Protease Inhibitor in Vaginal Fluid: Relation to Vaginal Components and Bacterial Composition. Reprod Sci 2014; 21:538-542. doi:10.1177/1933719113503416.
157. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653-656. doi:10.1086/318535.
158. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96:3086-3093.
159. Wong JH, Ye XJ, Ng TB: Cathelicidins: peptides with antimicrobial, immunomodulatory, anti-inflammatory, angiogenic, anticancer and procancer activities. Curr Protein Pept Sci 2013; 14:504-514.
160. Cole AM: Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306:199-230.
161. Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, Evans-Strickfaden T, Siddig A, Caliendo AM, Hart CE, Dezzutti CS: Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006; 22:788-795. doi:10.1089/aid.2006.22.788.
162. Smith JM, Wira CR, Fanger MW, Shen L: Human fallopian tube neutrophils-a distinct phenotype from blood neutrophils. Am J Reprod Immunol 2006; 56:218-229. doi:10.1111/j.1600-0897.2006.00410.x.
163. Cohen MS, Britigan BE, French M, Bean K: Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987; 157:1122-1125.
164. Kawano Y, Nakamura S, Nasu K, Fukuda J, Narahara H, Miyakawa I: Expression and regulation of thrombospondin-1 by human endometrial stromal cells. Fertil Steril 2005; 83:1056-1059. doi:10.1016/j.fertnstert.2004.09.035.
165. Burgener A, Boutilier J, Wachihi C, Kimani J, Carpenter M, Westmacott G, Cheng K, Ball TB, Plummer F: Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 2008; 7:4446-4454. doi:10.1021/pr800406r.
166. Mitchell C, Gottsch ML, Liu C, Fredricks DN, Nelson DB: Associations between vaginal bacteria and levels of vaginal defensins in pregnant women. Am J Obstet Gynecol 2013; 208:132.e1-132.e7. doi: 10.1016/j.ajog.2012.11.019.
167. Xu J, Holzman CB, Arvidson CG, Chung H, Goepfert AR: Midpregnancy vaginal fluid defensins, bacterial vaginosis, and risk of preterm delivery. Obstet Gynecol 2008; 112:524-531. doi:10.1097/AOG.0b013e318184209b.
168. Escribese MM, Rodriguez-Garcia M, Sperling R, Engel SM, Gallart T, Moran TM: Alpha-defensins 1-3 release by dendritic cells is reduced by estrogen. Reprod Biol Endocrinol 2011; 9:118. doi:10.1186/1477-7827-9-118.
169. Kumar R, Vicari M, Gori I, Achtari C, Fiche M, Surbeck I, Damnon F, Canny GO: Compartmentalized secretory leukocyte protease inhibitor expression and hormone responses along the reproductive tract of postmenopausal women. J Reprod Immunol 2011; 92:88-96. doi:10.1016/j.jri.2011.06.103.
170. King AE, Kelly RW, Sallenave JM, Bocking AD, Challis JR: Innate immune defences in the human uterus during pregnancy. Placenta 2007; 28:1099-1106. doi:10.1016/j.placenta.2007.06.002.
171. Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Gorogh T, Halec G, Kahn T, Hedderich J, Rocken C, Haag J, Waterboer T, Schmitt M, Giuliano AR, Kast WM: Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep 2013; 29:1962-1968. doi:10.3892/or.2013.2327.
172. Mhatre M, McAndrew T, Carpenter C, Burk RD, Einstein MH, Herold BC: Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transm Dis 2012; 39:591-597. doi:10.1097/OLQ.0b013e318255aeef.
173. Kai-Larsen Y, Agerberth B: The role of the multifunctional peptide LL-37 in host defense. Front Biosci (Schol Ed) 2008; 13:3760-3767.
174. Cooper MD, Roberts MH, Barauskas OL, Jarvis GA: Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal. Am J Reprod Immunol 2012; 68:116-127. doi:10.1111/j.1600-0897.2012.01149.x.
175. Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP: Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183:1243-1248. doi:10.1067/mob.2000.107383.
176. Wiechuła B, Cholewa K, Ekiel A, Romanik M, Dolezych H, Martirosian G: [HBD-1 and hBD-2 are expressed in cervico-vaginal lavage in female genital tract due to microbial infections]. Ginekol Pol 2010; 81:268.
177. Rizzo A, Losacco A, Carratelli CR: Lactobacillus crispatus modulates epithelial cell defense against Candida albicans through Toll-like receptors 2 and 4, interleukin 8 and human beta-defensins 2 and 3. Immunol Lett 2013; 156:102-109. doi:10.1016/j.imlet.2013.08.013.
178. Stock SJ, Duthie L, Tremaine T, Calder AA, Kelly RW, Riley SC: Elafin (SKALP/Trappin-2/proteinase inhibitor-3) is produced by the cervix in pregnancy and cervicovaginal levels are diminished in bacterial vaginosis. Reprod. Sci. 2009; 16:1125-1134. doi:10.1177/1933719109341998.
179. Fan SR, Liu XP, Liao QP: Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet 2008; 103:50-54. doi:10.1016/j.ijgo.2008.05.020.
180. Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL, Amortegui AA, Nicolazzo M, Sweet RL: Association between elevated neutrophil defensin levels and endometritis. J Infect Dis 2002; 186:792-797. doi:10.1086/342417.
181. Huppert JS, Huang B, Chen C, Dawood HY, Fichorova RN: Clinical evidence for the role of Trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract. J Infect Dis 2013; 207:1462-1470. doi:10.1093/infdis/jit039.